Loading...
•
Mar 31, 2025
Collegium Q1 2025 Earnings Report
Reported First Quarter 2025 Financial Results and Highlighted Recent Company Progress
Key Takeaways
Collegium Pharmaceutical delivered a strong first quarter in 2025, with significant revenue growth driven by both their ADHD and Pain portfolios. The company grew revenue by 23% year-over-year, made strategic investments in Jornay PM, and generated robust operating cash flows, increasing their cash position while also reducing debt.
Generated Q1'25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year.
Grew Jornay PM Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million.
Generated Net Revenue of $149.2 Million from the Pain Portfolio, Up 3% Year-over-Year.
Ended Q1'25 with Cash, Cash Equivalents and Marketable Securities of $197.8 Million.
Revenue by Segment
Forward Guidance
The company reaffirmed its full-year 2025 guidance for Product Revenues, Net, Adjusted Operating Expenses, and Adjusted EBITDA.
Positive Outlook
- Full-year 2025 Product Revenues, Net guidance of $735.0 to $750.0 million.
- Full-year 2025 Adjusted Operating Expenses guidance of $220.0 to $230.0 million.
- Full-year 2025 Adjusted EBITDA guidance of $435.0 to $450.0 million.
- Expected full year Jornay PM net revenue in excess of $135 million.
- Well positioned to execute on capital deployment priorities including business development, debt reduction, and share repurchases.
Challenges Ahead
- Unable to provide reconciliation of full-year 2025 guidance to GAAP measures due to unpredictable items.
- Forward-looking statements are subject to numerous important factors, risks and uncertainties.
- Risks related to unknown liabilities.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...